Simultaneous Integrated Boost (SIB) Technique in the Adjuvant Radiotherapy of Breast Cancer Patients.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Breast Cancer
- Sponsor
- Medical University of Graz
- Locations
- 1
- Primary Endpoint
- Acute Radiation induced toxicity (grade 2 or higher)
- Status
- Withdrawn
- Last Updated
- 3 years ago
Overview
Brief Summary
Adjuvant radiotherapy after breast conserving surgery has been shown to improve both local control and overall survival. Dose escalation of the tumor bed by addition of a boost after whole breast radiotherapy reduces the risk of local recurrence in invasive breast cancer.
Simultaneous integrated boost (SIB) techniques have been shown to provide more conformal treatment plans than conventional sequential boost, in addition, SIB enables a reduction in the overall treatment time by 1 week compared to conventional boost techniques.
The proposed study is aimed at evaluating radiation-induced toxicity in patients treated with breast-conserving surgery in combination with radiotherapy using SIB technique.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Invasive breast cancer or ductal carcinoma in situ
- •Breast conserving surgery
- •Complete tumor resection
- •Treatment with adjuvant radiotherapy of the breast
- •Indication for boost Irradiation
- •Given informed consent
Exclusion Criteria
- •Incomplete tumor resection
- •Mastectomy
- •Distant metastases at diagnosis
- •Unable to give informed consent
Outcomes
Primary Outcomes
Acute Radiation induced toxicity (grade 2 or higher)
Time Frame: Measurement 3 months after completion of radiotherapy
Toxicity score using Common Terminology for Adverse Events (CTCAE)